Cargando…
Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
Neutralizing monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein have been developed for the treatment of COVID-19. Whilst antibody therapy has been shown to reduce the risk of COVID-19-associated hospitalization and death, there is...
Autores principales: | Kurshan, Ashwini, Snell, Luke B, Prior, Lucie, Tam, Jerry C H, Graham, Carl, Thangarajah, Rajeni, Edgeworth, Jonathan D, Nebbia, Gaia, Doores, Katie J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914479/ https://www.ncbi.nlm.nih.gov/pubmed/36844257 http://dx.doi.org/10.1093/oxfimm/iqac012 |
Ejemplares similares
-
Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals
por: Lechmere, Thomas, et al.
Publicado: (2022) -
SARS-CoV-2 variants with shortened incubation periods necessitate new definitions for nosocomial acquisition
por: Snell, Luke B, et al.
Publicado: (2022) -
Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
por: Seow, Jeffrey, et al.
Publicado: (2023) -
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
por: Graham, Carl, et al.
Publicado: (2022) -
Real-Time Whole Genome Sequencing to Guide Patient-Tailored Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Snell, Luke B, et al.
Publicado: (2022)